See more : Rain Forest International, Inc. (RFII) Income Statement Analysis – Financial Results
Complete financial analysis of Bio Preventive Medicine Corp. (6810.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bio Preventive Medicine Corp., a leading company in the Biotechnology industry within the Healthcare sector.
- Raiffeisen Bank International AG (RAIFY) Income Statement Analysis – Financial Results
- ITM Semiconductor Co., Ltd. (084850.KQ) Income Statement Analysis – Financial Results
- Osang Healthcare Co.,Ltd (036220.KQ) Income Statement Analysis – Financial Results
- Smartphoto Group NV (SMAR.BR) Income Statement Analysis – Financial Results
- Sahathai Printing & Packaging Public Company Limited (STP.BK) Income Statement Analysis – Financial Results
Bio Preventive Medicine Corp. (6810.TWO)
About Bio Preventive Medicine Corp.
Bio Preventive Medicine Corp, a clinical-staged biotech company, focusing on early detection and prevention of diseases. The company offers solutions in prevention, screening, and monitoring chronic diseases and cancers management. It provides DNlite test, a series of patented and clinically validated non-invasive urine test for diabetic kidney disease management, such as DNlite-IVD103 and DNlite-DN_Score. The company was founded in 2014 and is headquartered in Zhubei, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 1.21M | 2.18M | 872.00K | 0.00 | 0.00 |
| Cost of Revenue | 125.00K | 229.00K | 99.00K | 0.00 | 0.00 |
| Gross Profit | 1.08M | 1.95M | 773.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 89.65% | 89.48% | 88.65% | 0.00% | 0.00% |
| Research & Development | 40.54M | 44.72M | 43.87M | 47.06M | 0.00 |
| General & Administrative | 23.71M | 20.99M | 20.17M | 16.36M | 0.00 |
| Selling & Marketing | 7.03M | 7.05M | 3.86M | 1.68M | 0.00 |
| SG&A | 30.74M | 28.04M | 24.03M | 18.04M | 0.00 |
| Other Expenses | 0.00 | 387.00K | -253.00K | 307.00K | -72.12M |
| Operating Expenses | 1.08M | 72.76M | 67.90M | 65.10M | -72.12M |
| Cost & Expenses | 73.77M | 72.99M | 68.00M | 65.10M | -72.12M |
| Interest Income | 756.00K | 413.00K | 405.00K | 350.00K | 0.00 |
| Interest Expense | 2.70M | 929.00K | 252.00K | 388.00K | 0.00 |
| Depreciation & Amortization | 8.24M | 16.26M | 21.36M | 21.23M | 0.00 |
| EBITDA | -62.34M | -53.75M | -45.61M | -43.22M | -51.87M |
| EBITDA Ratio | -5,160.68% | -2,469.13% | -5,230.62% | 0.00% | 0.00% |
| Operating Income | -70.58M | -70.01M | -66.98M | -64.45M | -72.12M |
| Operating Income Ratio | -5,842.88% | -3,215.94% | -7,680.62% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.70M | -929.00K | -252.00K | 269.00K | 0.00 |
| Income Before Tax | -73.29M | -70.94M | -67.23M | -64.83M | 0.00 |
| Income Before Tax Ratio | -6,066.64% | -3,258.61% | -7,709.52% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -73.29M | -70.94M | -67.23M | -64.83M | 0.00 |
| Net Income Ratio | -6,066.64% | -3,258.61% | -7,709.52% | 0.00% | 0.00% |
| EPS | -2.15 | -2.24 | -2.18 | -2.19 | 0.00 |
| EPS Diluted | -2.15 | -2.24 | -2.18 | -2.19 | 0.00 |
| Weighted Avg Shares Out | 34.09M | 31.73M | 30.83M | 29.60M | 29.60M |
| Weighted Avg Shares Out (Dil) | 34.09M | 31.73M | 30.83M | 29.60M | 29.60M |
Source: https://incomestatements.info
Category: Stock Reports